Financial News
Articles published by argenx SE
argenx to Present at Upcoming Investor Conferences
August 28, 2024
From argenx SE
Via GlobeNewswire
Tickers
ARGX
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
July 25, 2024
From argenx SE
Via GlobeNewswire
Tickers
ARGX
argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024
July 18, 2024
From argenx SE
Via GlobeNewswire
Tickers
ARGX
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
June 21, 2024
From argenx SE
Via GlobeNewswire
Tickers
ARGX
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
May 02, 2024
From argenx SE
Via GlobeNewswire
Tickers
ARGX
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
March 26, 2024
From argenx SE
Via GlobeNewswire
Tickers
ARGX
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
February 29, 2024
From argenx SE
Via GlobeNewswire
Tickers
ARGX
argenx to Present at Upcoming Investor Conferences
February 26, 2024
From argenx SE
Via GlobeNewswire
Tickers
ARGX
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
February 22, 2024
From argenx SE
Via GlobeNewswire
Tickers
ARGX
argenx Highlights 2024 Strategic Priorities
January 08, 2024
From argenx SE
Via GlobeNewswire
Tickers
ARGX
argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From argenx SE
Via GlobeNewswire
Tickers
ARGX
argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia
November 28, 2023
From argenx SE
Via GlobeNewswire
Tickers
ARGX
argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis
November 16, 2023
From argenx SE
Via GlobeNewswire
Tickers
ARGX
argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions
November 01, 2023
From argenx SE
Via GlobeNewswire
Tickers
ARGX
argenx to Present at Upcoming Investor Conferences
November 01, 2023
From argenx SE
Via GlobeNewswire
Tickers
ARGX
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.